Charles River updates its research database with addition of new tumor models

Charles River
CRO Charles River updated its Tumor Model Compendium database with the addition of new tumor models for early-stage oncology research. (Charles River)

Charles River Labs has updated its Tumor Model Compendium database with the addition of new tumor models for early-stage oncology research.

The latest updates include gastric and liver models, and new molecular data for leukemia, liver cancer, lymphoma, breast cancer and ovarian cancer. The compendium allows oncology researchers to access data that can identify the most appropriate tumor models. This hope is it will lead to more targeted study design from the beginning that could save time and money before clinical trials begin.

Charles River’s compendium includes models from a wide range tumor subtypes for both in vivo and in vitro oncology research. 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“The power of our oncology portfolio is stronger than ever,” Birgit Girshick, the company’s EVP for discovery and safety assessment, said in a statement. “Our scientists have worked diligently to accelerate cancer research and anticancer drug development efforts so patients can get the treatments they desperately need.”

Late last month, the CRO announced a partnership deal with Distributed Bio that gives Charles River’s client access to antibody libraries and integrated antibody optimization technologies. Under that agreement, the two will work to develop an end-to-end platform for therapeutic antibody discovery and development.